McCann FitzGerald LLP
McCann FitzGerald advising Horizon Pharma on proposed $1.1 billion acquisition of Hyperion Therapeutics, Inc.
We are acting as Irish counsel to Horizon Pharma plc in relation to its proposed acquisition of Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 billion in cash.
Select how you would like to share using the options below